AJU-A51 / AJU Pharm - LARVOL DELTA

Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study. (PubMed, Diabetes Obes Metab) - P3 | "Dapagliflozin and linagliptin FDC (AJU-A51) showed potent glucose-lowering effects, with good tolerability, in patients with T2D who had poor glycaemic control on metformin and linagliptin (ClinicalTrials.gov [NCT06329674])."

Clinical • Journal • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) - P3 | N=235 | Completed | Sponsor: AJU Pharm Co., Ltd.

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus